What is Derma Sensor?
Derma Sensor Inc. is at the forefront of health technology, dedicated to empowering primary care providers with advanced, non-invasive tools for effective skin cancer screening. Their flagship device leverages machine learning and spectroscopy to rapidly assess skin lesions for potential malignancy, providing results in seconds. The company's mission is to democratize access to crucial skin cancer checks, thereby improving patient outcomes and reducing overall healthcare expenditures. While the DermaSensor device has achieved CE Marking and is available in Australia and New Zealand, it awaits clearance for sale in other key markets.
How much funding has Derma Sensor raised?
Derma Sensor has raised a total of $21.8M across 4 funding rounds:
Debt
$150K
Series A
$11.5M
Debt
$162K
Other Financing Round
$10M
Debt (2020): $150K with participation from PPP
Series A (2020): $11.5M led by David Matlin, Chris Dewey, Dr. Maurice R. Ferre, and SternAegis Ventures
Debt (2021): $162K supported by PPP
Other Financing Round (2022): $10M featuring Ceros Capital Markets
Key Investors in Derma Sensor
SternAegis Ventures
SternAegis Ventures is a firm specializing in principal investing and investment banking, focusing on accelerating growth for qualified small businesses. Their expertise likely extends to identifying and supporting innovative ventures in the health technology sector.
Ceros Capital Markets
Ceros Capital Markets is a global platform that specializes in fundraising for MedTech and Biotech companies, particularly those with disruptive technologies in medical devices and digital health. Their involvement suggests a strategic alignment with Derma Sensor's mission.
David Matlin
David Matlin is an individual investor who participated in Derma Sensor's Series A funding. His involvement indicates a belief in the company's early-stage potential and its innovative approach to healthcare diagnostics.
What's next for Derma Sensor?
With the recent influx of major strategic investment, Derma Sensor is poised for significant expansion. The company's focus will likely shift towards obtaining regulatory approvals in additional major markets, scaling manufacturing capabilities, and broadening its sales and marketing efforts. This substantial backing from strategic partners indicates a strong market validation for their technology and a clear path toward achieving their goal of making accessible skin cancer detection a standard in primary care settings worldwide. Future growth will be driven by expanding the device's reach and further refining its diagnostic accuracy through ongoing R&D.
See full Derma Sensor company page
